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ABSTRACT OF THE DISSERTATION
Analysis of Regulatory Element Variation in Autism Spectrum Disorder
by
Evin Mitchel Padhi
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Genetics & Genomics
Washington University in St. Louis, 2022
Dr. Tychele N. Turner, Chair

Autism Spectrum Disorder (ASD) is a highly prevalent neurodevelopmental disorder that
affects over 2% of the population. Studies of this disorder have demonstrated that genetics plays
a strong role in the underlying etiology and over the past decade, substantial progress has been
made in elucidating the genetic architecture. Large-scale studies have now been conducted to
identify the genes involved in the genetic architecture by analyzing data from over 40,000
probands. However, the identification and characterization of regulatory elements involved have
remained non-trivial for many reasons. Generally, studies that have analyzed whole genome
sequencing (WGS) have demonstrated enrichment of de novo variants (DNVs), those that only
appear in a child, in categories of regulatory elements in probands when compared to unaffected
siblings. Therefore, a major goal in the field is to identify the individual regulatory elements that
are involved in ASD and analyze the functional effects of regulatory mutations. In this
dissertation, I present my findings focused on addressing this problem and present analyses and
experiments generalizable to many human genetic applications. I first detail the analyses

vii

identifying and characterizing the first regulatory element associated with ASD. Second, I
develop a method to analyze regulatory elements using large-scale reference genome data to help
pinpoint sub-regions within the enhancer that may be crucial for activity as displayed by
conservation across ~300 species. Last, I utilize massively parallel reporter assays (MPRAs) to
screen the effects of rare regulatory variants identified from WGS of ASD families to identify
functional patterns of these variants

viii

Chapter 1: The Genetics of Autism
1.1 Introduction
The characteristics of ASD were first clearly defined by Leo Kanner in the 1940s, where
he described ‘infantile autism’ as being distinct from other prior descriptions of children such as
schizoid or feeble-minded1. Currently, the DSM defines ASD as children with persistent deficits
in social communication and interaction and repetitive behaviors2, while there are also many comorbidities commonly found in individuals with ASD such as intellectual disability 3. Today,
ASD is one of the most prevalent neurodevelopmental disorders (NDDs), where it is estimated to
affect one in 44 children age 84. Studies of monozygotic twins with ASD have demonstrated that
there is a strong genetic component to this disorder, estimating that the heritability is up to 90%57.

ASD also experiences an extreme sex bias, where males to females are diagnosed at a ratio of

4:18,9. ASD is a complex disease, meaning there can be many different components contributing
to the underlying etiology such as genetics and other environmental factors. The high heritability
demonstrates that genetics plays a large role in the etiology of ASD, and to deeply understand
this disorder, genetic investigation is warranted.

1.1.1 The genetic architecture of ASD is complex
Interestingly, ASD is composed of a large range of phenotypes with some individuals
exhibiting only the core symptoms of impaired social communications and repetitive behaviors,
while others present with severe comorbidities such as intellectual disability. Underlying the vast
phenotypic heterogeneity are many genetic loci that can act additively or in isolation to cause an
individual to present with ASD and many possible comorbidities. Due to this, stratifying
1

individuals by phenotypic characteristics to study genetics has been successful in identifying
components of the genetic architecture of ASD10-12. An example of this is focused studies on
particular syndromes such as Fragile X11 and Rett12, which yielded some of the first insights into
the genes that play a role in NDDs and contribute to ASD.
Technological advancements that made it possible to study common variation in a scalable
and cost-effective manner using single nucleotide polymorphism (SNP) genotyping array had
major implications for the ASD field. This allowed for some of the first genome-wide inquiries
into the effects of genetic variation, specifically common SNPs, using genome-wide association
studies (GWAS). Common variation explains a substantial degree of liability13 and therefore has
strong predictive power for studies aimed at predicting phenotype from genotype. For instance,
polygenic risk scores (PRS) have been highly successful in examining the effects of common
variation in ASD demonstrating that probands tend to over inherit common variants compared to
unaffected siblings14. However, the biological insight that has come out of GWASs for ASD have
been limited due to the only recent identification of individual significant loci15.
One of the next major advancements in the field came from studying copy number
variation (CNV), where large regions of the genome are either duplicated or deleted. In individuals
with ASD, there is a higher rate of CNVs in certain chromosomal regions that have been shown to
confer a large degree risk and established cytogenetic chromosome bands like 16p11.2 and
7q11.23 to be bona fide ASD loci16-18. A drawback of this approach is that the CNVs are typically
very (> 1Mb) and contain many genes and it can be difficult to identify which genes within the
region are playing a causal role.
The effects of individual genes have been intensely studied through using whole-exome
sequencing (WES). WES is a technology that specifically can capture regions of the genome that
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encode sequences that are transcribed and then translated into protein products. This technology
has been widely utilized in studies of ASD and have identified many genes that are strongly
associated with ASD through de novo variation DNV, variants that are only observed in a child.
In addition to this, modeling WES data has provided other insights to the genetic architecture of
ASD and estimated there are 400-1000 genes involved19. Thus, while DNVs within a given gene
can be highly penetrant, many genes can contribute to ASD and each gene is only causal in a small
number of cases.
Collectively, technologies like microarrays that survey SNPs and CNVs, as well as WES,
have made monumental progress in advancing the knowledge of genes and loci involved in ASD.
However, these technologies though have inherent biases in them due to the fact they are only
designed to target certain regions of the genome, and thus are unable to capture certain types of
genetic variation. WGS provides an unbiased way to capture all single nucleotide variants (SNVs)
and small insertions and deletions. Therefore, WGS can provide insights to rare noncoding
variation, which has previously been unavailable to all other technologies. WGS faces many
problems in terms of interpretation of noncoding variants but has generally demonstrated that in
the Simons Simplex Collection, probands show a significant enrichment of DNVs in categories of
regulatory elements. This demonstrates that rare noncoding variation also plays a role in the
genetic architecture of ASD and is an additional avenue to that of common SNPs to explore the
roles that gene regulation plays in ASD.

1.1.2 Common variation and genome-wide association studies of ASD
Studying common variation using SNP microarrays was an exciting advancement for the
field of genetics, as this allowed for the characterization of predetermined variants across many
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different individuals also known as genome-wide association studies (GWAS). While GWAS are
limited to a predetermined set of single nucleotide polymorphisms (SNPs), they have been highly
successful in elucidating the genetic architecture of various traits and diseases 20-23. GWAS are
typically performed by examining common SNPs such that the variant is present at a reasonably
high frequency (minor allele frequency > 1%). Further, the study design of GWAS relies on
comparing the presence of these SNPs across proband and control cohorts to identify SNPs that
are more likely to be found in the proband cohort.
In addition to analyzing individual SNPs, a second approach is to characterize the effects
of many SNPs at once using PRS. In contrast to analyzing each SNP individually, this approach
allows for a bulk characterization of common variants and how they contribute to the heritability
of a trait or disease. Utilizing this approach has demonstrated that the largest source of liability in
ASD comes from common variants13 and that even in those individuals with other types of highly
deleterious rare variants, there can still be a contribution of common variants 14. Estimates of the
SNP-based heritability also highlights the success of this PRS based methods, as previously <1%
of the heritability could be explained by common variants, whereas considering the effects en
masse can explain ~50% of the heritability24. This approach has also been highly successful in
other applications such as human height and coronary artery disease 23,25,26, thus showing that
common variants largely exert weak individual effects across many traits but act en masse to make
significant contributions to heritability.
Initial GWAS in ASD involving cohorts of 1,000-2,000 individuals failed to identify any
significant SNPs that were replicable across cohorts27-30. Later studies with even larger sample
sizes of up to 16,000 individuals still had difficulty in identifying replicable associations with
individual SNPs31. A GWAS with over 25,000 ASD probands has now been able to identify the

4

first 5 significant SNPs that do show a replication signal, highlighting loci that are associated with
neuronal function and corticogenesis15. Additionally, this study examined how these SNPs are in
noncoding regions annotated to be making 3D contacts during human fetal corticogenesis and are
likely exerting their effects on ASD liability through regulatory effects 15. As sample sizes continue
to grow in future ASD GWAS not only will the predictive power begin to increase but more SNPs
will become robustly associated with ASD which in turn will lead to a better biological
understanding of the disease, and the ability to create better integrative models of multiple types
of variation in ASD. When combined with functional genomic annotations this will yield a much
better understanding of the neuropathology occurring in ASD as many common noncoding
variants, which are responsible for a large fraction of risk, occur in the proximity of regulatory
regions32.

1.2 The contribution of rare coding variation to ASD
1.2.1. Exome sequencing overview and models
The contribution of de novo variation, variants that arise in the parental germline, has been
heavily characterized in ASD using WES and WGS. The study design of these experiments differs
from those used throughout GWAS in various aspects. One of the main aspects is that to
appropriately identify DNVs, parents of a proband must also be sequenced so variants that are not
present in the parents can be identified. Historically, these studies are typically much smaller than
those in GWAS as the sequencing cost of performing these experiments is much higher than the
microarrays used in GWAS. However, with next-generation sequencing prices dropping rapidly
some of the newest exome-sequencing studies have cohorts of ASD probands that are as large or
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larger than those of recent GWAS studies15,33-36. These large cohorts have enabled deep
interrogation of the genes and pathways involved in ASD.
WES and WGS experiments rely on the use of statistical models to identify genes or other
genomic elements with an excess of DNVs compared to a background rate or null distribution10,3361.

One common approach is to derive an expected mutation rate per gene or genomic element

using a model that derives the expected rate using models that have rates for specific categories of
functional information. An example of this is denovolyzeR, this statistical framework creates genespecific expected mutation rates for different types of mutations by considering the length, local
sequence context, and average sequencing depth of each nucleotide38,62,63.

These expected

mutation rates can then be compared with the observed rates in disease cohorts to identify an excess
of DNVs in each gene or category. Alternatively, the expected number of mutations can be derived
using a human-chimpanzee fixed differences at locus64. Other models like TADA43 take a
Bayesian approach and can integrate de novo variation with other types of variants, which allows
for the integration of a case-control study design with that of a family-based one.

1.2.2. Exome sequencing in the Simons Simplex Collection
Applications of these models to WES data have been highly successful in identifying highconfidence ASD genes. Some of the earliest exome-sequencing studies were able to identify some
of what are now known as high-confidence ASD genes such as DYRK1A, CHD8, and
SCN2A39,42,45-47. A salient observation from these early studies was that the mutations being found
in the now high-confidence ASD genes were being found in either female cases or lower IQ
males42. Therefore, mutations in these genes have only been able to explain the more severe cases
of ASD in individuals who also have a diagnosis of intellectual disability. Other studies utilizing
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the TADA model first found evidence that there were two networks of genes involved in ASD,
one network involved in chromatin and transcriptional regulation, and a separate one for neuronal
communication44. These observations have been separately supported by orthogonal analyses
examining co-expression networks in the developing cortex, where ASD risk genes were mapped
onto these co-expression networks that involved transcriptional regulation and synaptic
development65. This study and others also provided further detail in showing that the chromatin
and transcription genes' expression peak in embryonic development, whereas the synaptic genes
are expression peaks postnatally65,66.

1.2.3. Use Of Reference population databases
With advancements in population-scale sequencing databases such as ExAC67 and more
recently gnomAD68, newer ASD WES studies have been able to take advantage of these population
reference databases33,69. Population reference databases have provided powerful gene-based
metrics such as the probability of loss-of-function intolerance (pLI), which characterizes a gene's
ability to tolerate protein-truncating variants (PTVs) by comparing the number of observed PTVs
to expected PTVs. These metrics are calculated from a sample database of over 100,000
individuals, without neurodevelopmental disorders, which provides a very high resolution to
identify constrained genes. Although the exact interpretation of pLI has been debated 70, other
scores like the loss-of-function observed/expected upper bound fraction (LOEUF) also provides a
way to quantify constraint while making fewer assumptions68.

1.2.4. Integration of constraint metrics and multiple types of variation applied
to large-scale exome sequencing
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Analyzing WES of over 10,000 ASD and using pLI metrics to stratify genes shows a large
proportion of risk conferred by de novo PTV exists in genes that are highly loss of function
intolerant (pLI > 0.995) and are enriched in cases when compared to controls 33. This strongly
reinforces that haploinsufficiency is one of the major mechanisms by which ASD genes are
disrupted, which has also been suggested from CNV studies 16-18. However, simulations have
suggested that gene discovery from de novo PTVs and missense mutations will begin to plateau in
larger sample sizes61. Thus, updating models to incorporate more information beyond de novo
variation is an important consideration for making efficient use of large-scale whole-exome data.
While TADA already incorporated multiple types of variation, a key advancement for gene
discovery in ASD has been an updated TADA model that includes more parameters such as pLI,
quantification of missense deleteriousness using the missense-badness Polyphen2 constraint score
(MPC), and CNV information has resulted in significant power increases to detect ASD genes 33,35.
These model updates have resulted in these studies being able to implicate over 183 ASD
genes with a false discovery rate (FDR) < .05. Excitingly these studies are now able to implicate
genes as playing a role in ASD predominantly using sources of variation besides de novo PTVs.
For example, DEAF1, SLC6A1, and KCNQ3 have now been implicated in ASD predominantly
due to de novo missense variation15,35. Other examples include PLXNA1, where its evidence comes
almost solely from inherited missense variation35. These genes implicated by de novo and
inherited missense variation may represent more moderate risk genes when compared to genes
implicated by de novo PTVs. Phenotypic analysis of these genes has yet to be performed thus far
so the relative risk of this class of genes is so far unknown.
In addition to rare inherited missense variation, the effects of rare inherited loss-of-function
(LoF) have also been studied. Probands are enriched for private inherited PTVs in conserved
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genes51, and the genes that confer risk from rare inherited variation are largely separate from those
that act through de novo variation36,71. The specific genes that confer risk through rare inherited
LoF variants have begun to be elucidated in a study by the SPARK consortia where they analyzed
over 40,000 ASD cases72. In this study, they analyzed the exome sequencing data in a two-stage
study design, where in the first stage they selected by looking for enrichment of DNVs and rare
inherited LoF variants with 10,000 cases. The second stage then performed a meta-analysis with
an additional 20,000 cases to analyze the prioritized genes for further enrichment of DNVs and
rare inherited LoFs.
Designing the study in this manner resulted in the detection of individual ASD risk genes
that are enriched for rare inherited variants. Detecting individual genes has been difficult in the
past because the effect size from this category of variation is weaker compared to that of de novo
PTVs and thus larger sample sizes are required. Through these efforts it was found that known
ASD and neurodevelopmental disorder (NDD) genes only explain ~20% of the over transmission
of LoF variants to probands, highlighting that rare inherited variation acts through a different class
of genes36. Additionally, known ASD or NDD genes explain ~70% of the risk conferred by de
novo variation36, reinforcing points made by earlier studies that gene discovery by de novo
variation alone will plateau soon61. In terms of genes identified, this study found 60 genes at the
exome-wide significance threshold, including five new risk genes. Of these 60 genes, they find
genes that have more moderate effects as well as one gene, NAV3, where the association is
essentially driven by rare inherited variation. Phenotypic analysis of these moderate-risk genes
yields exciting results showing that some of the rare inherited variants identified by this study are
not associated with cognitive impairment36.

9

1.2.5. Conclusions and open questions in the coding variation and GWAS
fields
These recent WES studies have represented exciting advances in the field of human
genetics for multiple reasons. For one, these studies are reaching staggering sample sizes ranging
from 10,000-40,000 cases33-36. This is a huge advancement from earlier exome sequencing studies
where the largest samples hovered around 2,000 cases 42,44-47. Due to what would now be
considered a smaller sample size for exome-sequencing of these studies they were largely
restricted to only looking at highly penetrant de novo PTVs. Because of this, they were only able
to explain cases that had more severe diagnoses. Though this is logical in hindsight that with a
limited sample size only signals from the highest effect size category will be found due to a lack
of power. Yet these studies did fantastic jobs at unequivocally implicating de novo PTVs and genes
involved in chromatin/transcriptional regulation and neuronal communication in ASD, providing
a solid foundation for future exome-sequencing studies to build off. Whereas, with these massive
exome-sequencing studies the genetics behind a broader range of cases and the contribution of
more types of variation are being illuminated, which is something that has remained elusive for
many years. Along with this integrating these new gene sets with advancing RNA-seq data sets is
providing a more fine-grained view of when and where these genes are acting during development.
Though there has been much progress made there are still a few main questions left to be
answered. First, we have still yet to characterize all types of variation and how they contribute to
ASD. For example, we still have only identified 5 significant common variant loci15 and only just
beginning to understand the effects of rare inherited PTVs36 and missense variants35. Naturally,
these will come with even larger sample sizes due to the smaller effect sizes of these types of
variation. An interesting question moving forward will be why are certain genes implicated
predominantly through rare inherited vs de novo variation? It will be interesting to see if as we
10

sequence more individuals if more DNVs are found in the genes implicated through rare inherited
variation. Otherwise, it could imply that de novo variation within these genes is largely nonviable
and that there is high selection acting on these genes. Functional characterization of these genes
and variants will help demonstrate any underlying principles.
A second question that remains is how do perturbations to two unrelated types of genes
lead to similar phenotypes? A consistent theme throughout these exome sequencing studies is how
is the enrichment of genes involved in chromatin/transcriptional regulation and neuronal
communication. How disruptions to these genes lead to similar neurodevelopmental phenotypes is
a question still at large. Studies have found little evidence for the hypothesis that the chromatin
and transcription factor genes are regulating those involved in synaptic signaling and neuronal
communication33. This is also unsurprising given that some of the co-expression networks these
genes are anti-correlated65 with one another. Though noteworthy studies have begun to use
CRISPR-Cas9 systems to knock out high-confidence ASD genes across different organoid models
and profile the effects with single-cell RNA-seq (scRNA-seq). Intriguingly, separately knocking
out ARID1B, CHD8, and KMT5B all similar effects and results in asynchronous development of
cortical neurons compared to wild type73. The three genes profiled in this study have all been
implicated in ASD due to de novo variation, thus it will be interesting to see if
chromatin/transcription regulation genes implicated through rare inherited variation perturb the
same phenotype in a more subtle manner or an altogether different process.

1.3 The contribution of de novo noncoding variation to ASD
While there have been significant efforts to understand the effects of coding variation in
ASD through WES, characterizing noncoding variation using WGS is an emerging area in human
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genetics. As of today, most studies have focused specifically on the role of DNVs in noncoding
regions of the genome. This is largely due to the sample sizes of WGS lagging behind those of
exome sequencing studies, where the largest WGS studies in ASD have examined the genomes of
~2,000 families37,41,49,52,53,59. Studies of WGS in ASD will likely follow a similar trajectory to
those of exome sequencing, where first the effects of highly penetrant DNVs are identified
followed by lower effect size DNVs and then inherited variation. Though the sample sizes to
identify these effects will likely need to be much larger than those of the exome-sequencing
counterparts41.
Initial analysis of WGS data from ASD families was limited due to only sequencing under
100 families74,75. However, one study conducted WGS analysis on families that were thought to
yield the most fruitful results because in most families no candidate genetic variants were detected
in microarray or WES data49. Firstly, by comparing the rates of DNVs in putative regulatory
elements in the fetal nervous system no enrichment was found in probands when compared to
siblings. However, restricting the analysis to only include elements nearby known ASD genes and
including private CNVs found statistically significant enrichment of disruptive events of these
putative regulatory elements close to known risk genes. Functional follow-up of one of these CNVs
found to harbor these elements demonstrated true neuronal regulatory element activity of these
elements as well49. Thus, this study provided some of the first concrete evidence of neuronal
regulatory element disruption playing a role in ASD.
Larger WGS studies of 500-2,000 families have expanded upon this result and investigated
the role of noncoding DNVs in large cohorts of families. Similar trends are observed where there
is a categorical enrichment of DNVs in various types of regulatory elements. These include
evolutionarily conserved and fetal brain promoters, embryonic enhancers, and RNA binding
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protein sites37,52,53 and represent an assortment of regulatory mutations that contribute to ASD.
However, a major barrier in the field has been the detection of individual regulatory elements that
contribute to ASD. Thus far we have been limited to categorical enrichment of DNVs in regulatory
elements and have yet to elucidate the individual elements that contribute to this signal.
Contrasting the largest WGS sequencing to study of ~2,600 families to that of similar-sized
exome-sequencing creates interesting comparisons. The exome sequencing studies around this
cohort size have been able to identify robust associations between protein-coding genes and PTV
DNVs42,44, while the WGS studies have struggled to move past categorical associations 37,52,53. This
is driven by a few different gaps in the field. One of the first is that it is difficult to interpret the
effects of noncoding variation, based on sequencing alone we cannot create a strong prior
hypothesis of how a variant will modulate sequencing activity (this is discussed in depth later). In
essence, it is difficult to separate variants that modulate regulatory element activity from those that
do not. Second, the noncoding component of the genetic architecture of ASD differs from that of
its protein-coding counterpart. This is illustrated by the earlier point that we have not been able to
detect strong associations in regulatory regions of the genome at similar sample sizes to those of
exome-sequencing studies.
Collectively, these observations generate a few different speculative hypotheses as to what
the noncoding architecture may look like. Given the difficulty in identifying functional noncoding
variants, one hypothesis is that the two are the same, it is just difficult to see with the complexities
of regulatory variants. This seems unlikely due to the differing recurrence rate of DNVs in the
Simons Simplex Collection alone as the recurrence rate of protein-coding DNVs is higher than
those of noncoding elements. A second hypothesis is that the number of regulatory elements is
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much greater than the number of protein-coding genes involved. Thus, because the number of
regulatory elements that contribute to ASD is so large detecting recurrence is rare.
This seems to be a biologically plausible hypothesis given that neuronal genes tend to have
many regulatory elements76. However, not all regulatory elements of a gene may contribute to
ASD, especially given that it seems there is redundancy built into some of these networks 77. The
third, and seemingly most likely hypothesis is that the effects of noncoding variation are much
weaker than that of protein-coding variation, and like how the effects of inherited variation have
begun to be elucidated with more families, so will the effects of noncoding variation. Some of
these hypotheses and issues can easily be addressed with larger datasets, however, these studies
will still be complicated by the complex regulatory code employed in noncoding regions discussed
next. It’s important to note that this will be a challenge beyond ASD and interpreting the effects
of noncoding variation presents a major challenge in many aspects of human genetics.

1.4 Biological interpretation of noncoding variation
1.4.1 The challenges, efforts, and modalities used to interpret noncoding
variation
Once a disease- or trait-associated SNPs or variants have been identified, biological
interpretation remains difficult since the vast majority of genetic variation exists in noncoding
regions of the genome78. This presents multiple challenges that are still being addressed in the field
of genomics but are 1) we cannot predict functional regulatory elements from sequence alone, 2)
all possible regulatory elements have not been identified yet, 3) the effects of sequence variation
on regulatory elements are difficult to predict, 4) linking regulatory elements to target genes is
complex, and 5) regulatory systems tend to be highly cell-type specific. These challenges are
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difficult but there exist multiple strategies to help overcome them that typically center around
incorporating functional genomics datasets or a high-throughput assay.
Interpreting noncoding variation has been a long-standing challenge in human genetics, as
such there have been many scale efforts to aid in understanding regulatory regions of the genomes
and the impact of variation. These include consortiums such as ENCODE, PSYCHENCODE,
Roadmap Epigenomics project, GTEx, and IGVF to name a few. Each of these efforts has tackled
the problem differently whereas PSYCHENCODE, ENCODE and Roadmap Epigenomics projects
have both focused heavily on profiling functional genomic aspects of various cell types and
tissues79-81. These have largely focused on histone post-translational histone modifications such as
H3K27ac and H3K27me3 that are supposed to demarcate regulatory regions 82. In addition to these
histone modifications, open chromatin regions are another type of chromatin profile that has come
into popularity to help identify regulatory elements using assay for transposable accessible
chromatin (ATAC)-seq83. A third epigenetic profile that is also heavily used is 3D genome
interactions that are measured by chromosome conformation capture such as Hi-C, a method that
measures chromosome conformation over a population of cells and regions that form chromatin
loops with gene promoters frequently overlapping with putative regulatory elements 84,85.

1.4.2 Functional genomics in neurodevelopmental systems
Functional genomic marks and datasets are highly cell-type specific, which makes profiling
them difficult in settings where the tissue is either hard to access or limiting. The fact that there
are over 86 to 100 billion neurons in the human brain86 and multiple dozens of different cell types
organized into over 100 different anatomical regions87 makes identifying all possible regulatory
systems in the brain a daunting challenge. Some critical understanding of brain regulatory systems
has come from examining specific anatomical structures of the brain at specific times in
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development thus reducing the complexity of the problem. Two structures that have had their
regulatory systems heavily profiled are the germinal zone and cortical plate. The germinal zone
consists of more neural progenitor-like cells and as they mature, they migrate towards the cortical
plate and create a gradient of neural progenitor cells to post-mitotic neurons88. These studies have
conducted comprehensive profiling of these structures in embryonic development using ATACseq, Hi-C, and scRNA-seq76,88-91 and have helped identify key regulatory systems that have helped
define the regulatory element space used in neurodevelopment. Other functional strategies have
included applying the same techniques to both mouse and organoid systems 92-96 which have
allowed for more cell-type-specific or higher resolution analysis. Collectively, these studies have
made great strides in tackling a complex problem using functional genomics experiments to begin
defining the regulatory systems used in neurodevelopment and provide a prioritized search space
to investigate the effects of noncoding variation.

1.4.2. Examples of the complexities of transcription factor binding
mechanisms
Defining the regulatory elements used in neurodevelopment or any context is the first step
to understanding the noncoding variation, but an important second step is then interpreting the
impact of a noncoding variant. Even when regulatory elements are defined this remains
challenging because the noncoding genome lacks the same kind of interpretation framework as
protein-coding regions of the genome. This is because regulatory elements act through using
complex patterns of transcription factor binding that then recruit cofactors such as the mediator
complex to activate transcription of a target gene97. The key challenge, therefore, lies in how a
change in DNA sequence affects the binding of a transcription factor to DNA.
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For example, the mechanisms of transcription factor binding at the γ-globin promoter have
been worked out in-depth and has highlighted the complexities of doing so. To briefly summarize
γ-globin switching, the repressor BCL11A binds to the γ-globin promoter to repress transcription
as part of the switch to β-globin genes. The mechanism of repression at this promoter is highly
complex and that transcription factor competition between BCL11A and NF-Y bind mutually
exclusive due to steric hindrance which leads to the decision between activation and repression 98.
Further, variants that impact these sites can then lead to prolonged-expression of γ-globin, but
elucidating which sites and variants are important is nontrivial99. A second example is the
transcription factor CRX, a terminal selector in retinal development. While CRX is a transcription
factor that has been traditionally thought to play an activating role in gene expression when bound
to a target regulatory element. Functional testing of these sequences through use of an MPRA
demonstrates CRX bound sequences have a wide range of activity spanning strong silencers and
strong enhancers. This leads to the conclusion that CRX binding patterns are insufficient to predict
patterns of regulatory element activity. These studies demonstrated that other features like
information content is what differentiates the activity of CRX bound sequences100,101. Intricacies
beyond patterns of transcription factor binding also add to the complexity of gene regulation, such
as 3D genome organization. One example of this in the 3D genome is how regulatory elements
target their cognate gene is still not well understood. Often the nearest gene to an enhancer is
concluded as being the target gene but there are many examples of regulatory elements skipping
one or many genes102. Additionally, studying the 3D genome using Hi-C is not able to resolve
higher-order contact structure which can complicate the interpretation of this data at certain loci,
though there are exciting new methods to begin to understand this103,104.

17

Mechanisms like the ones described will be relevant to the molecular mechanisms of ASD
as many of the genes identified from WES tend to play a role in gene regulation 33,42,59. WES
sequencing of ASD has identified various transcription factors and chromatin remodelers like
ARID1B and CHD8 which both have been identified to have a large effect on individual liability
when a DNV that is gene disrupting is present. For instance, DNVs within ARID1B is associated
with Coffin-Siris syndrome105,106, a severe neurodevelopmental disorder, whereas DNVs in CHD8
define a specific subtype of ASD where there is also macrocephaly and gastrointestinal
problems107. These genes are well implicated in neurodevelopmental disorders, but these
experimentally demonstrated molecular mechanisms of gene regulation also suggest that variation
within the target regulatory elements will likely play important roles in neurodevelopment as well.
Interpreting the effects of variation within these regions will require carefully thought-out
experiments as demonstrated by the cases of CRX and BCL11A.

1.4.3 Models used to interpret and prioritize noncoding variants
The in-depth dissection of CRX binding activity and the γ-globin promoter highlights many
of the complexities in working with regulatory elements that arise from intricate patterns of
transcription factor binding. These instances also underscore the challenges that are faced in
human genetic analyses using large-scale WGS data to pinpoint causal noncoding loci as most loci
have not been mechanistically characterized. Despite this multiple interpretation frameworks do
exist to aid in noncoding variant interpretation that typically relies on epigenetic marks. First, the
combined annotation dependent depletion (CADD) score, is a widely used model that predicts the
pathogenicity of a variant by comparing the frequency of simulated vs observed variants 108. Other
models rely on functional genomic data like deltaSVM using a k-mer support vector machine to
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quantify the predicted effect of a variant on an epigenetic mark at a locus 109. More recent models
like DeepSEA have utilized deep learning frameworks on massive datasets from ENCODE
consisting of transcription factor binding and chromatin profiles across cell types to predict the
effects of noncoding variants110.
However, the use of models that heavily rely on epigenetics marks as a predictor of
regulatory elements should be used with caution. There is mounting evidence that histone
modifications are not the main drivers of regulatory element activity and play a more supportive
role. This is first highlighted by experiments utilizing MPRAs to test the sufficiency of enhancer
annotations defined by epigenetics marks show that these modifications are not sufficient to define
regulatory element activity111. Second, the use of a multiplexed CRISPR-Cas9 editing approach
shows that many sequences that are driving gene expression at endogenous loci are unmarked and
do not have a typical enhancer epigenetic signature 112. Together these studies demonstrate that
histone modifications are neither necessary nor sufficient for regulatory element activity
complicating the use of these datasets for the interpretation of noncoding variation.
Other types of frameworks to help prioritize noncoding variants based on evolutionary
datasets exist such as PhastCons and PhyloP which quantify the degree of selection acting on a
site or nucleotide in a manner that is agnostic of functional data113. Generally, using evolutionary
alignments to identify regulatory elements has been highly successful114,115 and helped provide
some of the first genome-wide catalogs of regulatory elements. Interestingly, why certain
regulatory elements are so highly conserved is still not well understood. This is demonstrated by
experiments that have tested the regulatory element activity of ultra-conserved elements after
mutagenesis and have shown that these elements can largely function the same after mutagenesis
as before116.
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1.4.3 Phenotypic and developmental study of regulatory elements
Thus far I have discussed the molecular impact of variation within regulatory elements and
models to help prioritize such variants. Another major focus is studying the effects of such
elements and variants in in vivo systems to understand the impact these elements have on
development and the phenotypic outcome of variation. One resource that has played a major role
in understanding how regulatory elements act in development in VISTA browser in mouse
embryonic development115. This database is a collection of conserved sequences with validated in
vivo regulatory element through a lacZ reporter assay. This assay depends on a plasmid construct
where the regulatory element is cloned upstream of a reporter gene lacZ and is then injected in
mouse embryos114. After injection the embryo can then be stained with beta galactosidase and
where staining is observed in the embryo is interpreted to be where the regulatory element is active.
Experiments focused on understanding the role of VISTA enhancers have shown that they often
play a major role in high-level developmental processes, especially those occurring in the
brain59,117-120.
Similar approaches used to initially characterize regulatory elements can also be used to
understand the impact of noncoding variation. These approaches include using reporter constructs
that contain variants of interest to characterize how a variant changes patterns of activity or using
a CRISPR deletion or repression system. A striking example of this is the ZRS enhancer involved
in limb development, where deletion of this sequence causes limb malformations in mice 118.
Further high throughput testing of variants within this element has allowed for systematic
assessment of rare variants within this element that are associated with polydactyly 117. CRISPR
based approaches have for example focused on deletion of features of the 3D genomes and to also
understand genetic variation associated with limb malformations 121,122.
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In addition to mice as an in vivo model, zebrafish have also been powerful for regulatory
elements. One example of this is in early use of WGS in ASD where an enrichment of de novo and
private mutations were observed within fetal nervous system putative regulatory elements.
Functional assessment of a subset of these regions linked to DSCAM highlighted how these
regulatory elements are active through various structures in the central nervous system 49. Other
studies of ASD using zebrafish have focused on the regulation of the gene AUTS2, a transcriptional
regulator. Where in this study they first characterized the regulatory landscape of this gene in
zebrafish and validated them these elements in mice using a lacZ reporter assay. Collectively, the
techniques described in this section are crucial for in-depth characterization of regulatory elements
once a gene or locus has been defined. The main strength of these techniques is to perform indepth characterization of a handful of elements. However, performing these assays in a
multiplexed or high-throughput manner is still non-trivial.

1.4.4 Use of high-throughput systems to study regulatory elements
Traditional molecular biology techniques study regulatory elements on the scale of tens at
a time, like luciferase reporter assays. This has become a bottleneck due to the large number of
regulatory elements that exist within mammalian genomes and the pure number of noncoding
variants that are present within these regions32. Now with advancements in molecular biology and
scRNA-seq, many different experimental methods have been developed that perform in more
scalable manners. Largely, these advancements have come from implementing unique DNA
sequences that are associated with an element of interest and sequencing the abundance of these
barcodes as a proxy for some sort of activity in an assay. Most notably, MPRAs take advantage of
this system by creating a plasmid library where each different regulatory element sequence is
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uniquely associated with a barcode where a sequence's activity can be inferred by comparing the
abundance of this barcode in DNA and RNA. Accordingly, MPRAs serve as a method to assay
regulatory element sequences in a manner like a luciferase reporter assay, but in a manner that’s
scalable to tens of thousands of sequences101,123-128.
MPRAs create a scalable system to study regulatory elements and allowing for deep
dissection of the driving factors of regulatory mechanisms. Importantly, they use regulatory
element activity as a readout as opposed to a correlate of activity. For instance, this provides an
experimental way to test the effects of many genetic variants rather than k-mer models that
correlate sequence with epigenetic profiles. Many studies have now delved into the sequence
grammar of regulatory elements, but other designs have included elucidating which variants are
functional and are driving cis-expression quantitative trait locus (eQTL)124,125. Other studies have
aimed to characterize the impact of every possible noncoding variant in certain regulatory elements
by creating libraries where they had performed saturation mutagenesis 126. MPRAs have also been
used to prioritize variants at GWAS loci by identifying which ones have functional effects across
different diseases129,130, similar to what has been done in the eQTL studies. While MPRAs are still
a relatively new design, they have already become successful in several aspects of genetics.
However, MPRAs do have certain limitations. First, cellular context is a major
consideration for this experiment since regulatory elements are active in a cell-type dependent
manner. If the regulatory elements of interest are not active in the cell-type that is being assayed
this can complicate interpretation of result. Determining if an element should be active in a celltype is also non-trivial due to the complexities of interpreting epigenetic modifications and other
factors discussed earlier. Second, MPRAs have so far been performed in bulk where the effect in
the assay is summarized across all cell-types receiving the construct100,101,111,126-128,131. If
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differential effects are present across cell-types this will not be able to be identified from the
standard MPRA, though there have been recent efforts to develop a single-cell MPRA that will be
critical for future studies132.

1.5 Conclusions
Over the past decade, significant progress has been made in ASD genetics. Where at the
turn of millennia there was only a handful of genes associated with ASD, and these were mainly
due to the study of very severe forms of ASD. Through exome-sequencing studies, many different
genes have now been identified, and some have had an in-depth analysis of their function. Exciting
new studies have even started to elucidate genes through other types of variation beyond de novo
PTV, which represents a significant landmark in the advancement of human genetics. The
advancement of WGS has also allowed for novel identification of the types of regulatory elements
that contribute to ASD. While many questions remain in this field, a central question to the field
and my dissertation is the role of noncoding variation in the genetic architecture of ASD. Thus, I
focus my experiments and analyses here on this question. In this work, I pursue what types of
regulatory elements are involved in ASD and how they are disrupted. To do so here I describe 1)
the identification and characterization of the first noncoding element implicated in ASD, 2) a
strategy to prioritize noncoding elements using large-scale evolutionary data, and 3) the use of
high-throughput functional approaches to characterize noncoding mutations in ASD.
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Figure 1 Characterization of DNVs in hs737
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Figure 2 Copy number variation over hs737
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Figure 3 hs737 is a prenatal, brain specific enhancer
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Figure 4 EBF3 is the gene target of hs737
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Figure 5 EBF3 gene network analysis
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Figure 6 Consequence of coding and noncoding variation in EBF3
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Figure 7 Analyses of the ZRS enhancer with ACES
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Figure 8 ACES Workflow Overview
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Chapter 4 High-throughput Functional
assessment of de novo regulatory variation in
ASD
4.1 Introduction
In this chapter, I will describe how I designed and implemented an MPRA to test the
functional effects of noncoding DNVs, identified in individuals with ASD, in brain regulatory
elements. The overall goal was to implicate regulatory elements as relevant to ASD by using a
statistical framework and functional genomic approaches to increase the evidence for any given
element. First, I identified brain regulatory elements trending towards genome-wide significance
for an excess of DNVs in probands. Next, I designed an MPRA library to test the functional effects
of the identified DNVs and performed in vitro cell culture experiments across different neuronal
cell types to identify variants and elements that act in a cell-type-specific manner.

4.2 Results
4.2.1 ASD enhancer library design
Specifically, I identified DNVs from ASD WGS of 2,671 families 1 within putative
enhancers from the EpiMap repository2. The EpiMap repository is a catalog of regulatory element
annotations based on machine learning models used to predict genomic annotations based on
DNase I hypersensitivity sites across human tissues that are typically quite limited, for instance
fetal embryonic brain. This collection of putative regulatory elements greatly expands the search
space for potential elements that are implicated in ASD as it contains over 500,000 brain regulatory
element annotations.
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As this repository contains regulatory element annotations across different brain contexts,
I first created a merged list of annotations by collapsing annotations that were no more than 10 bp
apart to minimize any redundant annotations. In total, this created a list of 508,809 brain regulatory
elements that are active throughout developmental and adulthood which had 11,628 probands and
7,913 unaffected sibling DNVs. Due to the difficulty in interpreting the effects of noncoding
variation, I aimed to identify variants that are likely to be highly penetrant by applying a second
filtering step to look at enhancers that only had proband DNVs or only had sibling DNVs. The
sibling DNVs represent a control set of DNVs that should not be functional, essentially testing
how often an excess of DNVs should be functional. I next ran the statistical model fitDNM1,3 using
the length-mutation rate model to identify any elements that have a significant excess of DNVs or
are trending towards this threshold. As most elements only have a singular mutation, the average
p-value for elements in the proband cohort is 0.031 and 0.021 for siblings and currently do not
likely represent true ASD regulatory elements. To identify candidates that are more likely to be
true ASD elements, I performed a second filtering step, where I applied a p-value threshold of
.001. Applying this filter identified elements with at least two DNVs in either cohort (Figure 8)
and I validated DNVs status by manually analyzing WGS using samtools t-view4 to examine the
if there was any evidence of the alternate allele in any other family members. Elements where the
t-view validated the DNVs and that did not completely overlap repeat elements were then selected
for synthesis, this included 16 proband only and 5 siblings only elements. Additionally, for an
element to be selected for synthesis it also had to meet a length criterion (> 230 bp) so that it could
be synthesized on a single oligonucleotide. Elements that both validated and had a p value below
the threshold tended to be below the synthesis limit (Figure 8), also representing a bias in this
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method where I have more power to identify significance in shorter regulatory elements. For the
final library design, I included each of the identified DNVs within the regulatory elements as well
as the reference allele. For a positive control, I included regions of the RET+3 enhancer and a SNP
shown to alter its regulatory activity5. For negative controls, I created shuffled versions of each of
the reference alleles to disrupt any transcription factor binding motifs that would be driving
sequence activity. Use of shuffled negative controls is common to test that sequence activity is
truly being driven by transcription factors and not some alternative sequence feature such as GC
content for instance. I also included a sequence that when cloned will only contain the promoterreporter gene combo only as a baseline control, which in this case is hsp68 and DsRed-Express2.
This sums to a total of 68 different regulatory elements, where each element was barcoded 12
times for a total of ~800 barcodes in the library. For this library, I chose to use hsp68 as the
promoter due to its high basal activity, this in turn will allow for robust detection of small effects.
The main goal of this MPRA is to measure the effect of single-nucleotide variants, which should
have relatively small effect sizes because they are not making large perturbations to the sequence
content of the regulatory element. For this reason, I barcoded each element 12 times, as barcodes
act as technical replicates for an element to aid in detecting small effects.
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Figure 9 EpiMap elements with recurrent mutations.
EpiMap brain elements were first stratified wether they contain proband only or sibling only DNVs. Significance
was then calculated using fitDNM (see methods). X axis is the p-value from fitDNM, y axis is length. Horizontal
line represents the synthesis limit. Vertical line represents a p-value threshold where elements past this line are
false positives.

To test whether noncoding variants in these individuals with EpiMap brain DNVs were the primary
variant of interest, I analyzed protein coding DNVs in these individuals. I first examined the
number of coding DNVs within these individuals and I observe that most of these individuals only
have a single coding DNV (Figure 9B), which is like the whole SSC cohort (Figure 9A). Next, I
observe that most of the coding DNVs are missense and synonymous variants as expected and are
not occurring in known NDD genes (Figure 9C&9D). The contribution of polygenic variation in
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these individuals is also minimal in most cases. Collectively, this demonstrates that the
contribution from other types of variation in these individuals is minimal and thus these variants
represent reasonable candidates for highly penetrant noncoding DNVs.

A

B

4.2.2 Transfection of ASD enhancer library and quality control
First, I performed barcode sequencing to assess the dynamic range of barcode abundance
in my plasmid DNA pool after cloning. I detected ~80% of my total barcodes in the plasmid pool
suggesting a low dropout rate during the cloning procedure with ~50% of my elements having at
least 10 barcodes present (Figure 10A). The dynamic range of the plasmid pool counts spanned 2-

C

fold in log10 space, demonstrating that no set of barcodes was over or under abundant (Figure
D
10B).
WES studies have identified several lines of evidence disruptions to neuronal cell types are
important in the underlying pathology. Therefore, I selected four different neuronal cell lines to
perform the MPRA experiment in, those being Neuro2a (mouse neuroblastoma), HT-22 (mouse
hippocampal), SK-N-SH (human neuroblastoma), and SH-SY5Y (a subclone of SK-N-SH). I
extracted RNA after transfection from four replicates for each of the cell lines and prepared
barcode sequencing libraries from the extracted RNA and plasmid pool DNA. After counting
Figure 10 Coding variation in the SSC and individuals with EpiMap enhancer DNVs.
A) Distribution of coding DNVs per individual in the SSC. B) Distribution of coding DNVs in individuals with DNVs in EpiMap
brain elements of interest. C). Effects of coding DNVs in the EpiMap SSC cohort stratified by SFARI score. D) Count of the type
of DNV effects across all genes in EpiMap SSC cohort.

barcodes in the DNA and RNA across all replicates for each cell line, the RNA barcode counts
within each cell line had a Pearson correlation >0.99, indicating the technical variation in these
experiments was minimal. There was no correlation between the DNA normalized RNA counts vs
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plasmid DNA counts which indicates that there is true regulatory element activity in these
experiments as the fold change is not completely driven by DNA abundance.

4.2.3 Observed effects of regulatory DNVs across neuronal contexts
To identify which regulatory elements are active across the various cell types, I first
performed normalization of each construct to the basal level and identified significant effects
(expression effects) (Figure 6A). I then identified which variants significantly altered the
regulatory activity of the reference allele by normalizing each alternate allele to the reference and
identified significant effects (allelic effect) (Figure 6B). Generally, expression effects tended to
correlate well across the various cell lines (Figure 7A), however, the allelic effects tended to show
much more cell-type specificity (Figure 7B). On average, most sequences had a weak regulatory
sequence with the average fold change from basal across all elements in each of the lines being
1.51-fold change for HT-22 cells, a 1.31-fold change for Neuro2a cells, a 1.39-fold change for SK
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Figure 11 Effects of regulatory elements and variants across cell lines.
A) The average fold change of each element in the library when compared to the basal element. Colors represent different cell
lines, signifincance is calculated using a two-sided T-test comparing the basal element to each library member. B) The average
fold change of each variant when compared to its reference allele. Colors represent cell types and shape represents if the element
contained proband only or sibling only variants.

N-SH, and a 1.17-fold change for SH-SY5Y. Thus, most of these elements are either inactive or
have very weak activity.
Looking across all cell types, this analysis revealed that one element had a DNVs that
conferred strong hypermorphic activity across different lines, which were all identified as
significantly different from the reference allele (Figure 7C). Both variants had similar effects
across different lines, increasing the activity of the sequence ~2-fold across the different lines.
Utilizing 3D genome interaction data from multiple cell-type contexts, I was able to identify that
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this regulatory element is part of an interaction network involving MAPT-AS1 and MAPT6-8.
Specifically, I identified interactions for this element in induced pluripotent stem cells (iPSC)
derived- astrocytes, excitatory neurons, hippocampal neurons, and motor neurons. Further
generating hypotheses for which transcription factors may be impacted across all variants in the
library revealed that the hypermorphic allele of the MAPT regulatory element may be driven by a
BRCA1 gain of binding at the element (Figure 11A). The variant allele at this site is predicted to
cause a strong gain of binding and BRCA1 is highly expressed across the cell-lines assayed in a
non-specific manner.
A

B

Figure 12 Predicted motif disruptions of EpiMap DNVs and expression profiles.
A) Motifs predicted to be disrupted by DNVs using motifbreakR (see methods) sorted by the strength of the effect. Red indicates a gain
of binding effect where blue indicates a loss. B) Expression profiles of these transcription factors across cell lines. Count values were
log2(TPM +1) transformed. K562 represents a non-neuronal cell lines to identify neuronal specify of any the transcription factors.

Integrating functional genomic datasets and motif analyses identified a strong
hypermorphic variant at a regulatory element linked to MAPT across various neuronal cell contexts
by analyzing promoter-capture Hi-C data6. The interaction between this regulatory element is
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present across induced pluripotent stems cell that have been differentiated into excitatory, lower
motor, and hippocampal neurons as well as primary astrocytes. This demonstrates that this is a
broad neuronal interaction which is consistent with MAPT being a general marker of mature
neurons. While MAPT is a neuronal marker, the expression of this gene is low in cycling neural
progenitor cells present in scRNA-seq datasets from fetal neocortical development9, as well as in
the cell lines used in these experiments. This is contradictory with the results from the MPRA that
show this regulatory sufficient to drive reporter gene expression in neuroblast-like contexts. MAPT
has been demonstrated to be highly regulated by nature antisense RNAs which will act to act to
keep MAPT protein product level low10 but this does not fully explain the low transcript level in
these cell types. This leads to the hypothesis that other regulatory mechanisms may be acting at
this locus acting antagonistically to this experimentally identified enhancer. Additionally, this
highlights that MAPT may be in a primed state to be expressed once neural progenitor cells
progress to the next step of differentiation.
Performing motif analysis highlights at this regulatory element the effect of the
hypermorphic allele is driven by a gain-of-binding event for BRCA1, a known tumor suppressor
gene11. BRCA1 is well annotated to have a role in DNA-damage response but has also been
experimentally shown to associate with RNA polymerase II and has a transcription activation
domain12. Interestingly in RNA-seq datasets from the neocortical development, BRCA1 and MAPT
show mutually exclusive patterns of expression where BRCA1 is active in cycling progenitor cells
and MAPT in all cell types that have left the cell cycle9. Mechanistically, I hypothesize that the
variant that results in a gain-of-binding event will cause BRCA1 to drive the expression of MAPT
prematurely in neural progenitor cells which then may cause an early exit of the cell cycle leading
to altered neurodevelopmental trajectories that then manifest in ASD.
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4.3 Discussion
In this chapter I describe work performing high-throughput characterization of regulatory
DNVs identified from in the SSC. Currently in the field of neurodevelopmental genetics there is a
notable lack of power to detect genome-wide significant regulatory elements in ASD13, integrating
functional genomics experiments and datasets can help provide orthogonal support when statistical
power is lacking1. Here, I used a newly annotated putative brain regulatory elements and found
that many elements were trending towards genome-wide significance, but none of the elements
pass the multi-test correction threshold.
To further assess the elements that were trending towards genome-wide significance I
designed an MPRA library centered on these regulatory elements and their corresponding DNVs
and performed the experiment across multiple cell lines. First, this showed that most of the
elements had weak but significantly different activity from the basal construct. Similar trends were
observed for the effects of the variants on regulatory element activity, many of them caused weak
but significantly different activity from the reference allele (Figure 10). Second, across the
different cell lines those that had human origins tended to have more variance in their
measurements as well as lower effect sizes (Figure 10). This could be due to technical differences
such as differences in transfection efficiency, species specific effects, or cell type composition
across the lines. Notably, SK-N-SH is comprised of morphological cell types which may contribute
to the higher observed variance14. Additionally, SHSY-5Y is derived from the neuroblast subtype
of SK-N-SH and is noted to display spontaneous conversion back to the neuroepithelial subtype
which may also contribute the observed variance14.
Collectively, this work highlights the use and challenges of MPRAs in human genetics. In
this library there is high uncertainty regarding whether these regulatory elements regulatory
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elements are truly involved in ASD due to insufficient statistical power. Analysis of more WGS
of ASD families will help aid this in the future and combined with MPRAs will further the reveal
the various classes of regulatory elements and their mutations that lead to ASD. The experiments
here have also described an interesting type of regulatory mutation that displays different
properties from those described in the characterization of hs737 1. However, more mutations
regulatory mutations need to be characterized to understand how prevalent this class of mutations
is. Future experiments should carefully design around the cell-type specificity of the regulatory
elements in question. In these experiments I may be missing the true effects of these regulatory
elements due to the use of in vitro cell lines.

4.4 Methods
4.4.1 DNVs in 2671 autism families
I accessed DNV data from

Wilfert et al.

15

through SFARI Base (accession:

SFARI_SSC_WGS_2a, https://base.sfari.org/).

4.4.2 Statistical assessment of DNVs
A

list

of

EpiMap

Brain

enhancers

was

downloaded

from

(http://compbio.mit.edu/epimap/#analysis-datasets) and converted to hg38 coordinates using
liftOver16,overlapping annotations and those that were less than 10 base pairs apart across different
tissues were then collapsed into a single annotation using bedtools merge17 to create a nonredundant list of putative regulatory element annotations. The merged annotation list was then
intersected with the SSC DNV call set and filtered for elements that contain only proband or sibling
DNVs. An excess of DNVs at the locus was then assessed using a modified version fitDNM1,18 for
noncoding regions. Briefly, an expected number of mutations for a given locus is derived with the
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following 𝜆 = 𝑁 ∗ 2 ∗ ∑𝑙1 ∑41 𝑚 , where 𝑚 is the probability of observing a mutation of a
trinucleotide to any other trinucleotide. Thus, this method derives an expected value of mutations
based on the trinucleotide frequencies at a locus of interest. Significance is then calculated with
𝑝 = 1 − 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝑀 − 1, 𝜆) to test the null hypothesis that there is no elevated mutation rate at
the locus of interest.

4.4.3 Selection of regulatory elements for oligonucleotide synthesis and design
Elements were then considered for synthesis if they achieved a p-value < 1e-4 and met the
following validation criteria: 1) the identified DNVs had an allele balance of ~0.5 in the proband
and no reads containing the variant allele in the parents when manually inspecting the WGS data
using samtools t-view4, 2) the regulatory element was made up no more than 50% repeat content,
3) the element was shorter than the feasible synthesis limit for constructing an oligonucleotide
library, 4) the variant alleles were not present in gnomAD 19. In total I selected 32 regulatory
elements for synthesis each with 2 different variant alleles, a shuffled negative control generated
using MEME-suite20 and additionally included the biallelic RET+3 allele which is known to have
strong regulatory element activity in neuronal cell lines 5. Additionally, an oligo that would result
in a construct only containing the reporter gene and basal promoter was also included to be able to
calculate what the regulatory element activity of each element is. Each element in the library was
barcoded 12 times for a total of 828 barcodes.

4.4.4 MPRA library construction
Synthetic oligonucleotide libraries were ordered from IDT in the form of an oPool and
cloned into pJK0321 with the promoter and reporter gene removed using NEB HiFi assembly.
Library complexity was then assessed by performing a targeted PCR and next-generation
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sequencing on the barcodes of the intermediate library to ensure there was equal representation of
each barcode. After ensuring sufficient representation of each barcode, hsp68 and DsRed2 were
then cloned into the intermediate library using restriction ligation cloning with PacI-SpeI sites
present within the synthetic library and barcode diversity was assessed again.

4.4.5 Cell lines
Neuro2a (ATCC CCL-131) were purchased from ATCC and grown under standard
conditions (DMEM + 10% FBS and 1% Penicillin Streptomycin).
SK-N-SH (ATCC HTB-11) were purchased from ATCC and grown under standard
conditions (DMEM + 10% FBS and 1% Penicillin Streptomycin).
SHSY-5Y (ATCC CRL-2266) were purchased from ATCC and grown under standard
conditions (DMEM/F12 + 10% FBS and 1% Penicillin Streptomycin).
HT22 (SCC129) were purchased from Millipore Sigma and grown under standard
conditions (DMEM=High Glucose + 10% FBS and 1% Penicillin Streptomycin).

4.4.5 Mammalian cell culture transfection
Each line cell was cultured in the standard media described above and 500,000 cells were
plated per well in a 6-well plate, seeding a total of 4 replicates per line. Each replicate was
transfected 24 hours after seeding using lipofectamine 3000 (Invitrogen L3000015) mixed with
2ug of the final plasmid library using the standard protocol.

4.4.6 Transfection of cell lines and library generation
~48 hours after transfection cells were harvested and RNA was extracted using NEB
Monarch Total RNA Miniprep Kit (NEB #T2010S) and treated with DNase (TURBO DNase
Invitrogen AM2238) followed by cDNA synthesis with SuperScript IV (Invitrogen 1809150). Two
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PCR reactions per replicate were then performed targeting specifically the barcodes by priming
off the reporter gene to ensure PCR products only came from plasmids that contain the regulatory
element and reporter gene. An additional two PCR reactions were also performed on the plasmid
library to generate a library that would represent the abundance of the barcode in DNA. The final
libraries across all replicates for a given line were then pooled and sequenced to a depth of 20M
reads.

4.4.7 MPRA sequencing data analysis
To analyze the sequencing data from transfections, barcodes were first counted from the
resulting fastq files from the NovaSeq where only barcodes that an exact match to a designed
barcode was found were considered. Barcodes that then had more than 800 reads across all RNA
replicates and the DNA pool were then considered for downstream analysis and normalized to
sequencing depth using counts per million (CPM). Reproducibility was assessed between
biological replicates by calculating the Pearson correlation between the CPM normalized RNA
barcode counts.
The activity for each element was then calculated by averaging the RNA/DNA fold change
for each barcode of an element within a replicate, and then averaging the barcode fold changes to
calculate the activity for each element within a replicate. These averages were then used to derive
an expression effect to compare whether the activity of the regulatory elements across biological
replicates was significantly different from that of the basal construct containing only the promoter
and reporter gene using FDR corrected p-values from a two-sided T-test. Allelic effects were then
identified to examine whether any variants significantly altered the activity of the reference allele
using a similar strategy. A two-sided T-test was again used to compare if the average RNA/DNA
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fold changes were significantly different between reference and alternate alleles after performing
an FDR correction.

4.4.8 Transcription factor motif and cell line expression analysis
For motif analysis, motifBreakR with default parameters was used to identify overlapping
transcription factors and the effect of the variant allele on transcription factor binding 22 and
scanned the HOCOMOCO v11 database23. The list of transcription factors whose binding sites
were predicted to be disrupted by the variant were then used to query publicly available RNA-seq
data for HT2224, SK-N-SH25, SHSY-5Y26, and K56227 to identify any neuronal specific effects.
All fastqs were download from gene expression omnibus and quantified using salmon with
pseudoalignment option28 to generate TPM normalized values which were then log2(TPM +1)
transformed for analysis.
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Chapter 5 Discussion
At the start of my Ph.D., the primary focus of autism genetics has been largely centered
around the effects of rare protein coding variation and common noncoding variation. These
categories of variation explain a substantial fraction of ASD cases and have represented major
advancements in the field. However, the understanding of de novo noncoding variation was still
limited because only aggregate signals across noncoding elements had been deeply assessed. In
this dissertation I furthered the understanding of how noncoding regulatory elements contribute to
ASD cases by 1) Identifying specific regulatory elements enriched in ASD cases leading to the
identification of hs37, 2) Utilized large-scale reference genome databases to deeply asses the
conservation of noncoding elements, 3) Used MPRAs to assess the function of regulatory elements
trending towards genome-wide significance and create a strategy for large-scale in vitro
assessment of noncoding variants.

5.1 hs737 significance
In this dissertation, I have described the identification and characterization of one of the
first enhancers involved in ASD. This discovery and characterization represent a great
advancement for the field of ASD genetics, as this is one of the first regulatory loci identified in
ASD1. Largely, the identification of regulatory loci has been difficult because of a lack of power
and the difficulties that are inherent to interpreting noncoding variation2. Given that hs737 only
reached nominal significance in our statistical analysis, we examined other lines of evidence to
test for the involvement of hs737 in ASD. These analyses included copy number variation,
functional characterization of the identified DNVs, chromatin state, 3D genome interaction, motif,
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transcriptomic, and phenotypic analyses. Collectively, this data showed that hs737 is a brain
specific enhancer that regulates EBF3 which we hypothesize is a master transcription factor of
chromatin genes involved in ASD and NDDs. Thus, these analyses highlight that regulatory
element who control the expression of genes that are responsible for high level regulation of gene
network may continue to be identified from WGS of ASD families. In addition, the analyses
presented here present a framework for studying future regulatory elements involved in human
genetic disease while also providing an example of what one of the putatively many types of
enhancers that are involved in complex neurodevelopmental disorders.
The data from hs737 also has interesting implications when thinking about the genotypephenotype connections. This is undoubtedly one of the core difficulties in human genetics as this
connection highly complex and not straightforward. In terms of ASD, individuals who have large
effect rare variants (e.g., CNVs at 16p11.2, DNVs in CHD8) tend to exhibit co-morbidities like
intellectual disability, gastrointestinal problems, seizures, or syndromic features. Whereas
individuals that have ASD but lack co-morbidities such as those listed have been observed to have
a strong contribution common variation3. However, the data from hs737 analyses suggest an
alternative route through genotype-phenotype path demonstrating that DNVs in a regulatory
element that control a high-level transcription factor in a cell-type and developmental specific
manner can result in ASD without severe co-morbidities.

5.2 ACES significance
To analyze data from the Vertebrate Genomes Project (VGP) 4 in a high-throughput
manner, we developed the computational workflow Analysis of Conservation with an Extended
list of Species (ACES). ACES makes use of the large amount of reference genome data generated
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by the VGP and identifies sequences within these reference genomes that display similarity to the
query sequence and creates a multi-sequence alignment that is used to then model sequence
evolution at the locus and a graphical fragment assembly (GFA) file. Using our method to query
the ZRS enhancer we interestingly found regions within the enhancer that display extreme
conservation when modeling that sequence alignment with phastCons5. To my knowledge, this
degree of conservation has not been demonstrated in regulatory elements where we are able to find
regions within the element that are almost perfectly conserved across all species within the VGP
for more than 50 bp. Though the functional significance of these conserved regions is unknown,
ACES serves to help prioritize regions for functional experiments and downstream analysis based
on conservation.
Interestingly, the role of conservation in regulatory elements is still not well understood,
despite this being the primary method of identification for certain elements 6-8. When highly
conserved regulatory elements are mutagenized they tend to retain their regulatory element activity
in vivo8, raising the question of why this degree of conservation is observed if highly conserved
enhancers can tolerate nucleotide variation and maintain function. The data from ACES only
further complicates this, as it demonstrates that this degree of negative selection is pervasive across
many species and demonstrates that whatever the function of these conserved regions is, it is vital
to many organisms.

5.3 EpiMap-SSC MPRA significance
Hs737 is one of the first examples of a regulatory element implicated in ASD but to have
a deep understanding of how the regulatory genome is implicated in ASD I sought to identify and
characterize other regulatory elements using MPRAs. This resulted in the identification of an
enhancer linked to the neuronal marker gene MAPT, which has been widely implicated in
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neurodegenerative disorders9 and recently in studies of common variation in ASD10. The number
of loci implicated through common variation is still limited, but this highlights that that rare and
common variation in ASD may converge on similar regulatory mechanisms which has been
recently demonstrated at chromosome 16p as well11.
In comparison to hs737, this analysis highlights a very different type of regulatory element
that may be involved in ASD. Proxies of regulatory element activity show that hs737 is very
specifically active in neuronal development where the MAPT regulatory element forms contacts
with its target promoter across diverse cell types. This is further supported by the expression
patterns of EBF3, hs737’s target gene, and MAPT; where EBF3 is very tightly expressed and
MAPT is expressed broadly in neurodevelopment. Examining the target genes of the of each
element also shows differing levels of constraint to loss of function mutations, where EBF3 is
highly constrained (pLI = 1, LOEUF = 0.15) and MAPT is more tolerant to loss of function (pLI
= 0.01, LOEUF = 0.57). Gene function also vastly different between the two, EBF3 is a
transcription factor that controls the expression of many downstream chromatin genes whereas
MAPT encodes tau which helps form the cytoskeleton of neurons. The different properties of these
genes lead to the hypothesis that different types of regulatory perturbations occur in these elements
to then converge on ASD. When looking at the molecular effects of the DNVs within these
regulatory elements hs737 mutations cause a repressive effect on reporter gene activity whereas
the MAPT variant creates a hypermorphic allele of the regulatory element. This is consistent with
the observed properties of these genes, since MAPT is not haplo-insufficient its likely that a variant
that lowers the activity of a regulatory element would not be causal in ASD. Thus, these
experiments have highlighted a potential separate class of mutations then those observed in hs737
where the mutations cause overexpression of unconstrained genes involved in neuronal
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maintenance and function. Further statistical and functional analysis of WGS of ASD families will
highlight whether these trends hold true with more robust statistical power and possibly highlight
other classes of mutations involved.

5.2 Future directions
5.2.1 Dissecting the regulatory properties of hs737
First, we have still yet to identify the exact cell-type that hs737 is active in. One experiment
that could be done to elucidate this is to create a construct that contains hs737 cloned upstream of
a fluorescent reporter gene and inject these into mouse embryos and perform single-cell RNA
sequencing on mouse brains throughout embryonic development. For the analysis, cells would be
clustered by gene expression profiles excluding the reporter gene. Then after performing clustering
analysis, reporter gene expression could be unmasked and thus any cells that GFP expression
would then be the cell-types where hs737 is active. This could also help provide more evidence as
to the exact transcription factors that are being impacted by the variants we have identified in this
enhancer, as it would define a cell-type that we could begin to examine expression profiles of the
transcription factors that we have hypothesized to impacted. Where if the transcription factor was
absent from the cell-types that hs737 is active in, we can rule out that transcription factor.
Conversely, have a cell-type expression profile where hs737 is in also defines a search space for
possible transcription factors. However, identifying which transcription factors are responsible for
gain-of-function from this data alone would still be challenging. Additional experiments to
characterize the exact effects of the DNVs could be to do the same experiment as described as
above, but now with the ASD alternate alleles that we have identified. Then by comparing the
expression profiles of the alternate alleles with that of the reference allele variants that confer gainof-function effects in certain cell-types could be identified.
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A second experiment for gaining a deeper understanding of this enhancer would be to
perform a saturation mutagenesis experiment using an MPRA. This experiment would create every
possible single nucleotide change in the regulatory element one at a time, where each sequence
would then be readout through its association with a unique barcode. One immediate challenge
with this experiment is the length of hs737, which is ~1.2kb long. This becomes an issue due to
the limits of synthesizing DNA, which is currently ~280 bp, which results in either the regulatory
element needing to be broken up into multiple windows for this analysis or a more complex cloning
strategy. Though once the library is cloned standard MPRA workflows can then easily be used for
performing the experiment and analysis. The resulting data from this MPRA would also help better
get at which transcription factor binding sites are being impacted by these variants but also help
identify all important binding sites throughout the element. However, while we have some prior
hypotheses that some of the hs737 variants result in loss of binding that alter regulatory element
activity if the variant effects are driven by gain of binding effects this will likely still be difficult
to interpret from the data. This is because gain-of-binding events will not leave the same type of
footprint in the data, where when there is an important binding site being perturbed there will be
many sites that highlight the important nucleotides. Whereas gain-of-binding will have a different
signature in the data where it may just be a single change that is highlighted with no other changes
nearby appearing significant, thus making it difficult to identify which nucleotides contribute to
this event. At minimum though this experiment will be able to help verify gain-of-binding events
by identifying these signatures.
If both cell-type tracking experiment and the mutagenesis experiments are performed, this
will greatly narrow down the putative transcription factors down that are important to hs737. Thus,
once having both datasets a next experiment could be to perform experiments either using
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CRISPRi or hairpin RNAs to knockdown the transcription factors predicted to be important to
hs737 and then perform a luciferase reporter assay with the hs737 reference. Here my hypothesis
is that if a transcription factor is impacted by the DNVs we have found then knocking it down and
performing the luciferase reporter assay should recapitulate the effects of the variant. Alternative
experiments to verify this could include a chromatin-immunoprecipitation qPCR to measure the
transcription factor binding on the plasmid.

5.2.2 Understanding hs737’s influence on neurodevelopment
So far, I have described experiments to dissect the regulatory properties and the upstream
regulatory network of hs737, yet another important avenue is to explore how this enhancer
modulates phenotype. Experiments exploring this could be done in a variety of different models
such as cerebral brain organoids to gain relevant insight into the neurodevelopmental mechanisms
in humans or mice to understand the behavioral effects. Regardless of model used, a crucial
experiment is to knockout out this enhancer and perform molecular profiling using scRNA-seq or
scATAC-seq. This would yield direct insight as to the exact role hs737 plays in neurodevelopment.
Based off our prior data I hypothesize that there would be defects in mature cortical neurons due
to that hs737 forms a loop domain with EBF3 in fetal corticogenesis and that it is a developmental
specific enhancer from mouse ENCODE data. While bulk approaches of these methods could be
used, this will limit the interpretation of the data to the genes or peaks that are on average across
all cell-types differentially regulated. All relevant information of cell-type specificity would
largely be lost. These experiments are like those first described in the earlier section yet yield
slightly different insights, performing the knockout at the endogenous locus will result in knowing
exactly how this element controls neurodevelopment. Whereas the earlier experiments purely
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describe where the element is active and give no information to phenotype. They are similar
experiments but produce complimentary data, however, it may not be necessary to do both. Given
that hs737 regulates EBF3 which in turns controls the expression of a network involving many
chromatin and transcription factor genes, it is very likely that the knockout experiment would show
many altered cell-type trajectories and populations that would not be observable from the cell-type
tracking experiment.

5.2.3 ACES future directions
The development of ACES to analyze reference genome from the Vertebrate Genomes
Project has revealed interesting highly conserved noncoding regions across many species 12. From
these analyses alone though we do not understand if these regions are more critical to regulatory
element function compared to other regions within the ZRS enhancer. To elucidate the role of
these conserved regions within ZRS a lacZ reporter assay could be performed where the differing
conserved regions are each deleted isolation and how these affect activity throughout the limb bud
at E11.5. If these experiments show no changes, it may be necessary to move to different time
points which would prevent whole mount staining but in this case that would be okay since there
is already a defined well-defined specificity for the ZRS enhancer. If there are differential effects
of the deletions in the lacZ reporter assay it would then be interesting to move into performing a
CRISPR editing experiment and knock out the regions at the endogenous locus in the mouse
genome.
From here various experiments could be performed but one of the most interesting that
could be performed is to see how these deletions play a role in limb phenotypes. From previous
literature, its known that just a 17 bp snake specific deletion can cause defects in limb
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development13, so in essence performing this experiment one would be able to compare the
phenotypic effects between regions of the same enhancer that show positive selection and negative
selection. The role of conservation in regulatory elements is still not fully understood, so these
experiments have the potential to provide further insight to this.
Another approach that could be taken to understand the role of these highly conserved
regions is through using population and human genetic methods. For example, given that ZRS is
associated with preaxial polydactyl14 one analysis that could be done is to compare whether the
conserved regions have higher rates of variation in individuals with limb malformations compared
to controls. On the flip side of this, with large scale WGS reference catalogs now15,16 available a
comparison could also be made to see which regions within the element are depleted of variation
within control populations. This analysis may be difficult to do with current data, as typically
constraint/depletion of variation has been quantified on a 1kb scale across the genome, so moving
to a higher resolution may be difficult. However, to overcome this, patterns of variation across
many different highly conserved regions defined by ACES could be examined and to see if on a
global scale these regions display any unique patterns. Finally, an interesting question that remains
is how pervasive these highly conserved elements are throughout the human genome and whether
they define specific aspects of regulatory elements. Similar analyses have been done looking for
conservation on a smaller scale and was able to create some of the first genome-wide regulatory
element catalogs6,7. With much greater data, it is curious to think about if this analysis will reveal
the finer grain details of regulatory elements. At the time of writing this the Vertebrate Genomes
Project has strict data usage policies on how many loci can be examined in a study.
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5.2.4 EpiMap-SSC MPRA future directions
Performing this MPRA on these EpiMap regulatory elements with recurrent DNVs in
probands and siblings identified a MAPT regulatory element with strong hypermorphic effects.
The first experiment that should be done moving forward is a validation of this effect using a
luciferase reporter assay. Once the variant effect is to validate through this assay the next
experiment would be to knockdown BRCA1 and perform the luciferase assay again. Since the
variant is predicted to cause a gain-of-binding for BRCA1, I hypothesize that knocking down
BRCA1 should negate the effect of the variant and it should appear the same as wild-type.
Alternatively, doing so may enable other complex patterns of transcription factor binding and an
effect different from wild type may be observed.
The regulatory landscape of MAPT is highly complex, thus another follow up experiment
would be to use CRISPRi to repress this regulatory element and survey the effects on MAPT and
MAPT-AS1 expression. If repression of this element results in decrease of either of these genes it
provides a definitive link between the regulatory element and these genes. After performing these
experiments to provide definitive links between BRCA1, the regulatory element, and MAPT, other
follow ups should focus on how perturbation of MAPT expression or even more specifically this
regulatory element affect neuronal differentiation for example using CRISPRi and iPSC cells.
Where CRISPRi or CRISPRa is used to repress or activate the promoter of MAPT and this
regulatory element in separate replicates and measure how these perturbations affect
differentiation of neural progenitor cells into more mature neuronal like states. As mentioned
earlier, BRCA1 is highly expressed in cycling neural progenitor cells and thus this gain-of-binding
event likely causes premature expression of MAPT, which is normally expressed in maturing
neurons. Based on this observation, I hypothesize that over or under would lead to deficits in
progression of normal neuronal maturation.
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A second set of experiments could also be designed where this MPRA library is transfected
into more relevant neuronal cell-types. As an example, using induced pluripotent stem cells that
have been differentiated into neural progenitors or maturing neurons would provide a completely
different context to test this library in. It is possible that because I used neuroblastoma cell lines
that I may be missing many of the relevant effects in this library due to the wrong transcription
factors and cellular environment present.

5.3 Summary
To summarize, in this dissertation I describe the identification and characterization of the
first ASD enhancer, a method to analyze evolutionary sequence data, and characterization of ASD
regulatory DNVs at scale. In this work I have uncovered interesting properties of regulatory
elements both in terms of ASD and patterns of sequence evolution.
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